{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:44:28Z","timestamp":1782776668102,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["GuiKe-AB25069017"],"award-info":[{"award-number":["GuiKe-AB25069017"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation","award":["2024GXNSFAA010101"],"award-info":[{"award-number":["2024GXNSFAA010101"]}]},{"DOI":"10.13039\/501100012543","name":"Youth Science Foundation of Guangxi Medical University","doi-asserted-by":"publisher","award":["GXMUYSF202420"],"award-info":[{"award-number":["GXMUYSF202420"]}],"id":[{"id":"10.13039\/501100012543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project","award":["S2021098"],"award-info":[{"award-number":["S2021098"]}]},{"name":"Guangxi medical and health appropriate technology development and popularization application project","award":["S2022070"],"award-info":[{"award-number":["S2022070"]}]},{"name":"National Key Clinical Specialty Construction Project"},{"name":"Guangxi Medical And Health Key Discipline Construction Project and Guangxi Key Clinical Specialty Construction Project."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05098-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:03:28Z","timestamp":1778083408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The global clinical trial landscape of lung cancer cellular therapy current status trends and scientific challenges"],"prefix":"10.1007","volume":"17","author":[{"given":"Chang","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Jian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ji","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"5098_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45\u201352. https:\/\/doi.org\/10.5114\/wo.2021.103829.","journal-title":"Contemp Oncol (Pozn)"},{"key":"5098_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"5098_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jconrel.2017.11.036","volume":"269","author":"HM Abdelaziz","year":"2018","unstructured":"Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269:374\u201392. https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.036.","journal-title":"J Control Release"},{"key":"5098_CR4","doi-asserted-by":"publisher","unstructured":"Smolarz B, \u0141ukasiewicz H, Samulak D, Piekarska E, Ko\u0142aci\u0144ski R, Romanowicz H. Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature). Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26052049.","DOI":"10.3390\/ijms26052049"},{"key":"5098_CR5","doi-asserted-by":"publisher","unstructured":"Alexander M, Kim SY, Cheng H, Update. 2020: Management of Non-Small Cell Lung Cancer. Lung. 2020;198:897\u2013907. https:\/\/doi.org\/10.1007\/s00408-020-00407-5","DOI":"10.1007\/s00408-020-00407-5"},{"key":"5098_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2019.06.005","volume":"202","author":"M Terlizzi","year":"2019","unstructured":"Terlizzi M, Colarusso C, Pinto A, Sorrentino R. Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacol Ther. 2019;202:140\u20138. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.06.005.","journal-title":"Pharmacol Ther"},{"key":"5098_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000443368","volume":"61","author":"O Tetsu","year":"2016","unstructured":"Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy. 2016;61:223\u201335. https:\/\/doi.org\/10.1159\/000443368.","journal-title":"Chemotherapy"},{"key":"5098_CR8","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1002\/wnan.1654","volume":"13","author":"W Wang","year":"2021","unstructured":"Wang W, Hao Y, Liu Y, Li R, Huang DB, Pan YY. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13:e1654. https:\/\/doi.org\/10.1002\/wnan.1654.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"5098_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/2159-8290.Cd-18-1022","volume":"8","author":"Z Piotrowska","year":"2018","unstructured":"Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, et al. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018;8:1529\u201339. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-1022.","journal-title":"Cancer Discov"},{"key":"5098_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"5098_CR11","doi-asserted-by":"publisher","unstructured":"Olejarz W, Sadowski K, Szulczyk D, Basak G. Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25147743.","DOI":"10.3390\/ijms25147743"},{"key":"5098_CR12","doi-asserted-by":"publisher","first-page":"e70726","DOI":"10.1002\/cam4.70726","volume":"14","author":"S Capolla","year":"2025","unstructured":"Capolla S, Rasool M, Toffoli G, Dal Bo M. CAR-T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View. Cancer Med. 2025;14:e70726. https:\/\/doi.org\/10.1002\/cam4.70726.","journal-title":"Cancer Med"},{"key":"5098_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"MC Vo","year":"2025","unstructured":"Vo MC, Tran VD, Nguyen VT, Ruzimurodov N, Trung DT, Kim SK, et al. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? J Hematol Oncol. 2025;18:91. https:\/\/doi.org\/10.1186\/s13045-025-01744-9.","journal-title":"J Hematol Oncol"},{"key":"5098_CR14","doi-asserted-by":"publisher","first-page":"963689724123189","DOI":"10.1177\/09636897241231892","volume":"33","author":"J Han","year":"2024","unstructured":"Han J, Zhang B, Zheng S, Jiang Y, Zhang X, Mao K. The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer. Cell Transpl. 2024;33:9636897241231892. https:\/\/doi.org\/10.1177\/09636897241231892.","journal-title":"Cell Transpl"},{"key":"5098_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/1759-7714.14375","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Chen F, Li J, Pu Y, Yang C, Wang Y, et al. CAR-T cell therapy for lung cancer: Potential and perspective. Thorac Cancer. 2022;13:889\u201399. https:\/\/doi.org\/10.1111\/1759-7714.14375.","journal-title":"Thorac Cancer"},{"key":"5098_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20. https:\/\/doi.org\/10.1186\/s12943-023-01723-z.","journal-title":"Mol Cancer"},{"key":"5098_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"AN Miliotou","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC, CAR, T-cell Therapy. A New Era in Cancer Immunotherapy. Curr Pharm Biotechnol. 2018;19:5\u201318. https:\/\/doi.org\/10.2174\/1389201019666180418095526.","journal-title":"Curr Pharm Biotechnol"},{"key":"5098_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14712598.2020.1688298","volume":"20","author":"AG Pockley","year":"2020","unstructured":"Pockley AG, Vaupel P, Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther. 2020;20:23\u201333. https:\/\/doi.org\/10.1080\/14712598.2020.1688298.","journal-title":"Expert Opin Biol Ther"},{"key":"5098_CR19","doi-asserted-by":"publisher","first-page":"989461","DOI":"10.3389\/fphar.2022.989461","volume":"13","author":"T Yang","year":"2022","unstructured":"Yang T, Xiong Y, Zeng Y, Wang Y, Zeng J, Liu J, et al. Current status of immunotherapy for non-small cell lung cancer. Front Pharmacol. 2022;13:989461. https:\/\/doi.org\/10.3389\/fphar.2022.989461.","journal-title":"Front Pharmacol"},{"key":"5098_CR20","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.7150\/thno.84710","volume":"13","author":"B Zhang","year":"2023","unstructured":"Zhang B, Ren Z, Zhao J, Zhu Y, Huang B, Xiao C, et al. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer. Theranostics. 2023;13:4449\u201368. https:\/\/doi.org\/10.7150\/thno.84710.","journal-title":"Theranostics"},{"key":"5098_CR21","doi-asserted-by":"publisher","unstructured":"Katiyar V, Chesney J, Kloecker G. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15143733.","DOI":"10.3390\/cancers15143733"},{"key":"5098_CR22","doi-asserted-by":"publisher","first-page":"175883592513202","DOI":"10.1177\/17588359251320280","volume":"17","author":"F Abodunrin","year":"2025","unstructured":"Abodunrin F, Olson DJ, Emehinola O, Bestvina CM. Adopting tomorrow\u2019s therapies today: a perspective review of adoptive cell therapy in lung cancer. Ther Adv Med Oncol. 2025;17:17588359251320280. https:\/\/doi.org\/10.1177\/17588359251320280.","journal-title":"Ther Adv Med Oncol"},{"key":"5098_CR23","doi-asserted-by":"publisher","first-page":"108711","DOI":"10.1016\/j.lungcan.2025.108711","volume":"207","author":"L Trudu","year":"2025","unstructured":"Trudu L, Rovesti G, Neri G, Pugliese G, Silingardi M, Brini L, et al. CAR-T for Lung Cancers: Challenges and Innovations. Lung Cancer. 2025;207:108711. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108711.","journal-title":"Lung Cancer"},{"key":"5098_CR24","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/2159-8290.Cd-24-0645","volume":"14","author":"MT Lotze","year":"2024","unstructured":"Lotze MT, Maeurer M, Quezada SA, Coukos G. Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage. Cancer Discov. 2024;14:1366\u20138. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0645.","journal-title":"Cancer Discov"},{"key":"5098_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40164-025-00679-8","volume":"14","author":"C Yang","year":"2025","unstructured":"Yang C, Liu Y, Huang Z, Liu S, Zhang X, Liu Q, et al. Recent advances and challenges of cellular immunotherapies in lung cancer treatment. Exp Hematol Oncol. 2025;14:94. https:\/\/doi.org\/10.1186\/s40164-025-00679-8.","journal-title":"Exp Hematol Oncol"},{"key":"5098_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2168479018782885","volume":"53","author":"S Stergiopoulos","year":"2019","unstructured":"Stergiopoulos S, Getz KA, Blazynski C. Evaluating the Completeness of ClinicalTrials.gov. Ther Innov Regul Sci. 2019;53:307\u201317. https:\/\/doi.org\/10.1177\/2168479018782885.","journal-title":"Ther Innov Regul Sci"},{"key":"5098_CR27","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"5098_CR28","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1056\/NEJMe1714680","volume":"377","author":"E Tran","year":"2017","unstructured":"Tran E, Longo DL, Urba WJ. A Milestone for CAR T Cells. N Engl J Med. 2017;377:2593\u20136. https:\/\/doi.org\/10.1056\/NEJMe1714680.","journal-title":"N Engl J Med"},{"key":"5098_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"5098_CR30","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/cm9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu Y, He S, Cao M, Teng Y, Li Q, Tan N, et al. Comparative analysis of cancer statistics in China and the United States in 2024. Chin Med J (Engl). 2024;137:3093\u2013100. https:\/\/doi.org\/10.1097\/cm9.0000000000003442.","journal-title":"Chin Med J (Engl)"},{"key":"5098_CR31","doi-asserted-by":"publisher","unstructured":"Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, et al. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000796.","DOI":"10.1136\/jitc-2020-000796"},{"key":"5098_CR32","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.2023.6252","volume":"329","author":"E Harris","year":"2023","unstructured":"Harris E. Cancer Moonshot Plan Announced. JAMA. 2023;329:1443. https:\/\/doi.org\/10.1001\/jama.2023.6252.","journal-title":"JAMA"},{"key":"5098_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/ppo.0000000000000316","volume":"24","author":"KB Goldberg","year":"2018","unstructured":"Goldberg KB, Blumenthal GM, Pazdur R. The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory Environment. Cancer J. 2018;24:131\u20135. https:\/\/doi.org\/10.1097\/ppo.0000000000000316.","journal-title":"Cancer J"},{"key":"5098_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.Ccr-20-2220","volume":"27","author":"RA de Claro","year":"2021","unstructured":"de Claro RA, Gao JJ, Kim T, Kluetz PG, Theoret MR, Beaver JA, et al. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program. Clin Cancer Res. 2021;27:11\u20134. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2220.","journal-title":"Clin Cancer Res"},{"key":"5098_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s43441-021-00296-7","volume":"55","author":"C Feng","year":"2021","unstructured":"Feng C, Virparia R, Mui ET. Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities. Ther Innov Regul Sci. 2021;55:881\u20138. https:\/\/doi.org\/10.1007\/s43441-021-00296-7.","journal-title":"Ther Innov Regul Sci"},{"key":"5098_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s43441-021-00371-z","volume":"56","author":"YG Gao","year":"2022","unstructured":"Gao YG, Roberts S, Guy A. Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot. Ther Innov Regul Sci. 2022;56:212\u20139. https:\/\/doi.org\/10.1007\/s43441-021-00371-z.","journal-title":"Ther Innov Regul Sci"},{"key":"5098_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134826","author":"C Tenopir","year":"2015","unstructured":"Tenopir C, Dalton ED, Allard S, Frame M, Pjesivac I, Birch B, et al. PLoS ONE. 2015;10:e0134826. https:\/\/doi.org\/10.1371\/journal.pone.0134826. Changes in Data Sharing and Data Reuse Practices and Perceptions among Scientists Worldwide."},{"key":"5098_CR38","doi-asserted-by":"publisher","first-page":"799455","DOI":"10.3389\/fimmu.2021.799455","volume":"12","author":"C Genova","year":"2021","unstructured":"Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol. 2021;12:799455. https:\/\/doi.org\/10.3389\/fimmu.2021.799455.","journal-title":"Front Immunol"},{"key":"5098_CR39","first-page":"69","volume":"9","author":"M Chechli\u0144ska","year":"2004","unstructured":"Chechli\u0144ska M, Duma A, Swierkowska K, Kami\u0144ska J, Steffen J. Sera of lung cancer patients affect the release of Th1, Th2 and monocyte-derived cytokines, and the expression of IL-2Ralpha by normal, stimulated mononuclear cells. Cell Mol Biol Lett. 2004;9:69\u201381.","journal-title":"Cell Mol Biol Lett"},{"key":"5098_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Araki K, Cardenas MA, Li P, Jadhav RR, Kissick HT, et al. PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program. Nature. 2022;610:173\u201381. https:\/\/doi.org\/10.1038\/s41586-022-05257-0.","journal-title":"Nature"},{"key":"5098_CR41","first-page":"159","volume":"66","author":"A Kasprzak","year":"2007","unstructured":"Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz). 2007;66:159\u201366.","journal-title":"Folia Morphol (Warsz)"},{"key":"5098_CR42","doi-asserted-by":"publisher","first-page":"864159","DOI":"10.3389\/fonc.2022.864159","volume":"12","author":"P Yang","year":"2022","unstructured":"Yang P, Qiao Y, Meng M, Zhou Q. Cancer\/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer. Front Oncol. 2022;12:864159. https:\/\/doi.org\/10.3389\/fonc.2022.864159.","journal-title":"Front Oncol"},{"key":"5098_CR43","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/1878-0261.13474","volume":"17","author":"F Hikmet","year":"2023","unstructured":"Hikmet F, Rassy M, Backman M, M\u00e9ar L, Mattsson JSM, Djureinovic D, et al. Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer. Mol Oncol. 2023;17:2603\u201317. https:\/\/doi.org\/10.1002\/1878-0261.13474.","journal-title":"Mol Oncol"},{"key":"5098_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/20468954.2025.2535939","volume":"13","author":"JAP Salda\u00f1a","year":"2024","unstructured":"Salda\u00f1a JAP, Flores-Robles D, Montes AC, Mill\u00e1n-Vega A, Sierra-Mart\u00ednez P, Perez-Santos M. Trivalent bispecific anti-MSLN(2)\/CD3 antibody for cancer treatment. Pharm Pat Anal. 2024;13:169\u201373. https:\/\/doi.org\/10.1080\/20468954.2025.2535939.","journal-title":"Pharm Pat Anal"},{"key":"5098_CR45","doi-asserted-by":"publisher","first-page":"925217","DOI":"10.3389\/fimmu.2022.925217","volume":"13","author":"W Zeng","year":"2022","unstructured":"Zeng W, Pan J, Fang Z, Jia J, Zhang R, He M, et al. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy. Front Immunol. 2022;13:925217. https:\/\/doi.org\/10.3389\/fimmu.2022.925217.","journal-title":"Front Immunol"},{"key":"5098_CR46","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2217\/fon-2021-0838","volume":"18","author":"J Chen","year":"2022","unstructured":"Chen J, Liu X, Zhang J, Huang Z, Zeng W, Hu J, et al. Frontline anti-PD-1\/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2022;18:1651\u201364. https:\/\/doi.org\/10.2217\/fon-2021-0838.","journal-title":"Future Oncol"},{"key":"5098_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2022.06.034","volume":"174","author":"JP Foy","year":"2022","unstructured":"Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1\/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur J Cancer. 2022;174:287\u201398. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.034.","journal-title":"Eur J Cancer"},{"key":"5098_CR48","doi-asserted-by":"publisher","first-page":"1038715","DOI":"10.3389\/fimmu.2022.1038715","volume":"13","author":"M Lin","year":"2022","unstructured":"Lin M, Huang Z, Chen Y, Xiao H, Wang T. Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1\/PD-L1 therapy. Front Immunol. 2022;13:1038715. https:\/\/doi.org\/10.3389\/fimmu.2022.1038715.","journal-title":"Front Immunol"},{"key":"5098_CR49","doi-asserted-by":"publisher","first-page":"217096","DOI":"10.1016\/j.canlet.2024.217096","volume":"598","author":"X Li","year":"2024","unstructured":"Li X, Shang S, Wu M, Song Q, Chen D. Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis. Cancer Lett. 2024;598:217096. https:\/\/doi.org\/10.1016\/j.canlet.2024.217096.","journal-title":"Cancer Lett"},{"key":"5098_CR50","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang J, Liu D, Wang Y, Liu L, Li J, Yuan J, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy. Gut. 2022;71:734\u201345. https:\/\/doi.org\/10.1136\/gutjnl-2020-321031.","journal-title":"Gut"},{"key":"5098_CR51","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00277-025-06467-y","volume":"104","author":"X Wang","year":"2025","unstructured":"Wang X, He X, Zhang T, Liu J, Zhao M. Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies. Ann Hematol. 2025;104:3129\u201351. https:\/\/doi.org\/10.1007\/s00277-025-06467-y.","journal-title":"Ann Hematol"},{"key":"5098_CR52","doi-asserted-by":"publisher","first-page":"9651","DOI":"10.1038\/s41467-025-65148-6","volume":"16","author":"EJ Carstens","year":"2025","unstructured":"Carstens EJ, Takahashi K, Sakamoto N, De Vizio M, Morgado M, Nikkhoi SK, et al. Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat Commun. 2025;16:9651. https:\/\/doi.org\/10.1038\/s41467-025-65148-6.","journal-title":"Nat Commun"},{"key":"5098_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/tcrm.S479686","volume":"21","author":"T Boucheron","year":"2025","unstructured":"Boucheron T, Chiche L, Penaranda G, Souquet M, Pegliasco H, Deturmeny J, et al. Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study. Ther Clin Risk Manag. 2025;21:273\u201382. https:\/\/doi.org\/10.2147\/tcrm.S479686.","journal-title":"Ther Clin Risk Manag"},{"key":"5098_CR54","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.apjon.2024.100549","volume":"11","author":"NM La-Beck","year":"2024","unstructured":"La-Beck NM, Owoso J. Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy. Asia Pac J Oncol Nurs. 2024;11:100549. https:\/\/doi.org\/10.1016\/j.apjon.2024.100549.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"5098_CR55","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.21037\/jtd-24-682","volume":"16","author":"Z Li","year":"2024","unstructured":"Li Z, Chu H, Huang S, Li R, Qiu B, Tan F, et al. Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer. J Thorac Dis. 2024;16:6579\u201394. https:\/\/doi.org\/10.21037\/jtd-24-682.","journal-title":"J Thorac Dis"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05098-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:54:47Z","timestamp":1782773687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5098"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05098-7","relation":{"references":[{"id-type":"doi","id":"10.1371\/journal.pone.0134826","asserted-by":"subject"}]},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data supporting the findings of this study are publicly available from the registries referenced in this work, including ClinicalTrials.gov, the European Union Clinical Trials Register (EU-CTR), and the WHO International Clinical Trials Registry Platform (ICTRP). Therefore, ethical approval was not required. All data were anonymized and analyzed in accordance with the terms of use of the respective databases. Not applicable. This study is a analysis of published literature and does not involve human participants, animals, or clinical data requiring ethical approval","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to partcipate"}},{"value":"We confirm that this manuscript is original, has not been published in whole or in part elsewhere, and is not currently under consideration for publication in another journal. All authors have approved the final version of the manuscript and agree to its submission to Discover Oncology. If accepted, the authors authorize the journal to publish the article under the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"945"}}